Therapeutic Solutions International Inc. (OTCMKTS:TSOI) jumped 20% after announcing the patent and new data filing covering JadiCells use and other therapeutic combination in COPD treatment. The studies involved intravenous JadiCells administration in animals treated with elastase, a protein that triggers lung deterioration similar to what happens in COPD.
JadiCells demonstrated superior lung damage reduction in animals relative to other stem cells such as bone marrow and adipose. Also, the animals that received JadiCells showed considerable reduction of the inflammatory protein toll-like receptor four expression and enhanced anti-inflammatory proteins MerTK expression.
Chief medical officer James Veltmeyer stated that the regenerative and ant-inflammatory impacts of JadiCels had been shown in a range of in vivo and in vitro settings. Veltmeyer added that considering COPD’s inflammatory nature and past studies demonstrating regenerative approaches’ potential in COPD, and the company evaluated JadiCells in established animal models of COPD. TSOI is thus worth watching in the coming weeks.
On Monday, TSOI stock surged 20% at $0.12 with more than 58.84 million shares, compared to its average volume of 12.65 million shares. The stock has moved within a range of $0.1019 – 0.1345 after opening the trade at $0.1025.